We are international
Donate
• about myeloma TEXT SIZE   
treatment options    back

STEP 3: INITIAL TREATMENT SELECTION - GETTING THE BEST TREATMENT
REFERENCES
08.10.11

STEP 3- REFERENCES

  1. High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma. Child. New England Journal of Medicine 2003:348:19

  2. Abstract “Standard Chemotherapy Compared With High-Dose Chemotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321” Barlogie (J Clin Oncol 24:929-936, 2006)

  3. Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group Rajkumar 2006 JCO

  4. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Barlogie 2007 British Journal of Hematology.

  5. Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial. Hulin 2009 Journal of Clinical Oncology Volume 27

  6. Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial. Reeder, Leukemia. 2009 July ; 23(7): 1337–1341. doi:10.1038/leu.2009.26.

  7. Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines.

  8. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma Richardson, BLOOD 2010, 116: 679-686

  9. Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial Mateos, JCO 2010 Vol. 28

  10. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomized controlled trial. Rajkumar Lancet Oncology 2010 January ; 11(1): 29–37. doi:10.1016/S1470-2045(09)70284-0.

  11. ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES: A CONTINUING MEDICAL EDUCATION SERIES Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management S. Vincent Rajkumar Am. J. Hematol. 86:57–65, 2011. Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/ajh.21913

  12. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Cavo. BLOOD 2011 117: 6063-6073

  13. Randomized multi-center, Phase 2 study (EVOLUTION) of combinations of BORTEZOMIB, Dexamethasone, cyclophosphamide, and lenalidomide in previously untreated Multiple Myeloma. Kumar 2012 BLOOD 119: 4375-4382 doi:10.1182/blood-2011-11-395749

 related articles